Company intelligence / Profile preview

Endofotonics

Ownership: Private
Development stage: Commercial

Overview

The SPECTRA IMDx™ system has demonstrated improved early detection rates for gastric cancer using real-time in-vivo Raman spectroscopy. Clinical trials commenced in 2020, and the product has reached commercial sales both outside and within China. Detailed published clinical results are not specified in public sources.

Therapeutic areas: Oncology
Modalities: DeviceAI-enabled diagnostic platformRaman spectroscopy-based technology
Industry: Medical Imaging

Beyond the preview

Go deeper on Endofotonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endofotonics.

Explore the full profile